Citation
Kempers, Steven, et al. "A Randomized Investigator-blinded Study Comparing Pimecrolimus Cream 1% With Tacrolimus Ointment 0.03% in the Treatment of Pediatric Patients With Moderate Atopic Dermatitis." Journal of the American Academy of Dermatology, vol. 51, no. 4, 2004, pp. 515-25.
Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol. 2004;51(4):515-25.
Kempers, S., Boguniewicz, M., Carter, E., Jarratt, M., Pariser, D., Stewart, D., Stiller, M., Tschen, E., Chon, K., Wisseh, S., & Abrams, B. (2004). A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology, 51(4), 515-25.
Kempers S, et al. A Randomized Investigator-blinded Study Comparing Pimecrolimus Cream 1% With Tacrolimus Ointment 0.03% in the Treatment of Pediatric Patients With Moderate Atopic Dermatitis. J Am Acad Dermatol. 2004;51(4):515-25. PubMed PMID: 15389185.
TY - JOUR
T1 - A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis.
AU - Kempers,Steven,
AU - Boguniewicz,Mark,
AU - Carter,Eric,
AU - Jarratt,Michael,
AU - Pariser,David,
AU - Stewart,Dan,
AU - Stiller,Matt,
AU - Tschen,Eduardo,
AU - Chon,Katie,
AU - Wisseh,Steve,
AU - Abrams,Beatrice,
PY - 2004/9/25/pubmed
PY - 2005/4/12/medline
PY - 2004/9/25/entrez
SP - 515
EP - 25
JF - Journal of the American Academy of Dermatology
JO - J Am Acad Dermatol
VL - 51
IS - 4
N2 - OBJECTIVE: To evaluate pimecrolimus cream 1% and tacrolimus ointment 0.03% in pediatric patients with moderate atopic dermatitis (AD). METHODS: 141 patients (aged 2-17 years) were randomized to treatment with pimecrolimus cream 1% (n=71) or tacrolimus ointment 0.03% (n=70) twice daily for 6 weeks. RESULTS: At day 4, local, application-site reactions were less common and of shorter duration with pimecrolimus than with tacrolimus. Incidence of erythema/irritation was 8% (6/71) with pimecrolimus compared with 19% (13/70) with tacrolimus (P=.039). Fewer patients receiving pimecrolimus (0%, 0/6) experienced erythema/irritation lasting >30 minutes, compared with those receiving tacrolimus (85%, 11/13; P <.001). Fewer patients reported itching with pimecrolimus (8%; 6/71) than with tacrolimus (20%; 14/70; P=.073). Incidence of warmth, stinging, and burning was similar in both groups; however, reactions lasting >30 minutes were fewer with pimecrolimus (0%, 0/14) than with tacrolimus (67%, 8/12; P <.001). More patients receiving pimecrolimus rated ease of application as 'excellent' or 'very good', compared with tacrolimus (76% vs 59%, respectively; P <.020). Efficacy was similar in both groups at day 43. Both treatments were generally well tolerated with no unexpected adverse events. CONCLUSION: Pimecrolimus cream 1% had better formulation attributes and local tolerability than tacrolimus ointment 0.03% while providing similar efficacy and overall safety in pediatric patients with moderate AD.
SN - 1097-6787
UR - https://www.unboundmedicine.com/medline/citation/15389185/A_randomized_investigator_blinded_study_comparing_pimecrolimus_cream_1_with_tacrolimus_ointment_0_03_in_the_treatment_of_pediatric_patients_with_moderate_atopic_dermatitis_
L2 - https://linkinghub.elsevier.com/retrieve/pii/S0190962204005511
DB - PRIME
DP - Unbound Medicine
ER -